<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828124</url>
  </required_header>
  <id_info>
    <org_study_id>CA015-003</org_study_id>
    <nct_id>NCT02828124</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer</brief_title>
  <official_title>A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in
      patients with liver cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 23, 2016</start_date>
  <completion_date type="Anticipated">October 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Adverse Events (AEs) at its worst grade</measure>
    <time_frame>Up to four years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs) at its worst grade</measure>
    <time_frame>Up to four years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuations</measure>
    <time_frame>Up to four years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to death</measure>
    <time_frame>Up to four years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of laboratory test toxicity grade shifting from baseline</measure>
    <time_frame>Up to four years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fridericia-corrected QT interval (Î”QTcF)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of different subject immunogenicity status</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum observed serum and/or plasma concentration)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (time of maximum observed serum and/or plasma concentration)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) (area under the concentration-time curve from time 0 to time t)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) (area under the concentration-time curve in 1 dosing interval)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau (concentration at the end of a dosing interval)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough (trough observed serum and/or plasma concentration, including predose concentrations and Ctau concentrations)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT (total body clearance calculated as dose divided by AUC(TAU)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss (apparent volume of distribution at steady-state)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz (volume of distribution of terminal phase)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI_Cmax (accumulation index; ratio of Cmax at steady-state to Cmax after the first dose)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI_Ctau (accumulation index; ratio of Ctau at steady-state to Ctau after the first dose)</measure>
    <time_frame>Up to four years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986183</intervention_name>
    <description>specified dose on specified days</description>
    <arm_group_label>Dose Escalation Monotherapy</arm_group_label>
    <arm_group_label>Dose Expansion Monotherapy</arm_group_label>
    <arm_group_label>Dose Escalation Combination Therapy</arm_group_label>
    <arm_group_label>Dose Expansion Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>specified dose on specified days</description>
    <arm_group_label>Dose Escalation Combination Therapy</arm_group_label>
    <arm_group_label>Dose Expansion Combination Therapy</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Must have advanced liver cancer that cannot be treated with surgery or other local
             methods

          -  Liver cancer is confirmed by a microscopic examination of tissue

          -  Liver disease is classified as 'A' by a standard method called Child-Pugh score

          -  Daily living abilities are classified as '0 or 1' by a standard method from the
             Eastern Cooperative Oncology Group (ECOG)

          -  Women must use contraception

        Exclusion Criteria:

          -  Prior liver transplant

          -  Increase in blood pressure in some of the veins entering the liver

          -  Cancer that has spread to the brain or the layers of tissue that cover the brain or
             spinal cord

          -  Infection with both hepatitis B and C, both hepatitis D and B, infection with HIV, or
             other infections

          -  Disease of the heart or blood vessels around the heart

          -  Active cancers within the last 2 years

          -  No more than 2 prior systemic treatments or other investigational agents except
             PD-1/PD-L1 or Ipilimumab (Part 2)

          -  Currently on anti-platelet or anti-coagulation therapy

          -  Radiotherapy within 4 weeks of treatment

          -  Any major allergies

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

